Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ATNM Actinium Pharmaceuticals Inc

0.00 (0.00%)
2024年6月17日 - 終了
名称 銘柄コード 市場 種別
Actinium Pharmaceuticals Inc ATNM AMEX 普通株式
  前日比 前日比 % 現在値 時刻
0.00 0.00% 7.82 09:00:00
始値 安値 高値 終値 前日終値
この銘柄の詳細情報 »


日付 時間 ソース タイトル
2024/6/1421:30PRNUSActinium Highlights Oral Presentation at EHA 2024 Annual..
2024/6/1121:30PRNUSActinium Announces Results of Actimab-A + CLAG-M Combination..
2024/6/1021:30PRNUSActinium Highlights Mutation Data from the Phase 3 SIERRA..
2024/5/1521:30PRNUSActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial..
2024/5/1507:38PRNUSActinium Announces Oral Presentation Detailing Improved..
2024/5/1321:30PRNUSActinium Announces Multiple Abstracts Highlighting its..
2024/5/0721:00PRNUSActinium Announces KOL Webinar to Highlight Recently..
2024/4/1821:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
2024/4/0121:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
2024/3/2620:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
2024/3/1120:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
2024/2/2621:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
2024/2/2321:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
2024/2/1006:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0614:15EDGAR2Form EFFECT - Notice of Effectiveness
2024/2/0307:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
2024/1/0221:30PRNUSActinium Announces Acceptance of Five Abstracts for..
2023/12/3007:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/3007:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/3007:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/3007:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/3007:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1122:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
2023/12/1121:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
2023/12/0822:00PRNUSActinium to Highlight Broad Potential of Targeted..
2023/12/0207:00EDGAR2Form 8-K - Current report
2023/11/1007:05EDGAR2Form DEF 14A - Other definitive proxy statements
2023/11/0621:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
2023/11/0305:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
2023/11/0222:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0222:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
2023/10/0420:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
2023/9/2722:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
2023/9/0721:40PRNUSActinium Pharma Presents Survival Data from Extended..
2023/8/3120:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
2023/8/2120:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
2023/8/1506:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1122:00EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/7/2420:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
2023/6/2620:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
2023/6/2321:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..


Delayed Upgrade Clock